JenaValve Technology develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. The Company is in late-stage clinical development of its next-generation transfemoral TAVR system in both the U.S. and CE mark countries for treating patients with severe aortic regurgitation or aortic stenosis.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.